AntiToxin Technologies Competitors

Seres Therapeutics is a commercial-stage company developing novel microbiome therapeutics for serious diseases. Our lead program, VOWST™, obtained U.S. FDA approval in April 2023 as the first orally administered microbiota-based therapeutic to prevent recurrence of C. difficile infection (CDI) in adults following antibacterial treatment for recurrent CDI and is being commercialized in collaboration with Nestlé Health Science. We are evaluating SER-155 in a Phase 1b study in patients receiving allogeneic hematopoietic stem cell transplantation to reduce incidences of gastrointestinal infections, bloodstream infections, and graft-versus-host disease as well as additional preclinical stage programs targeting Infection Protection in medically compromised patients. We are also conducting research to inform further development of microbiome therapeutics for ulcerative colitis. For more information, please visit http://www.serestherapeutics.com/ .

Vaxine Pty Ltd is a rapidly growing Australian biotechnology company based in Adelaide that has developed an impressive pipeline of vaccines against infectious disease, allergy, and cancer . Vaxine has developed the Advax range of proprietary polysaccharide adjuvants and is currently applying this state of the art adjuvant technology to development of vaccines against hepatitis B, pandemic influenza, Japanese encephalitis, West Nile virus, malaria, HIV and rabies, amongst others.

SAB Biotherapeutics is a clinical-stage, biopharmaceutical company developing a new class of immunotherapies leveraging fully human polyclonal antibodies. SAB has applied advanced genetic engineering and antibody science to develop transchromosomic (Tc) Bovine that produce fully-human antibodies targeted at specific diseases, including infectious diseases such as COVID-19 and influenza, immune system disorders including type 1 diabetes and organ transplantation, and cancer. The company is headquartered in Sioux Falls, South Dakota.